Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof
US11198851B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 4, 2017 |
| Grant date | Dec 14, 2021 |
| Priority date | — |
| Expiry date | Dec 17, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2502/1121
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method for ex vivo generating and expanding γδ Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors performed the induction of Foxp3+ expression in ex vivo human induced tumor-antigen specific CD4+ TCRγδ unrestricted T cells and the induction of autologous CD8-mediated T-cell responses against tumor-antigen specific FOXP3 expressing CD4+ TCRγδ unrestricted T cells. The inventors developed a method to ex vivo generated and expanded antigen specific Foxp3 expressing CD3+ TCRγδ+ unrestricted T cells, committed to exclusively exert regulatory activity, whichever culture condition of stimulation is. In particular, the present invention relates to a method for generating ex vivo γδ Foxp3+ regulatory T cells having the following phenotype: CD3+ TCRγδ+ Foxp3+.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.